These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 31267651)

  • 1. Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
    Melchior B; Mittapalli GK; Lai C; Duong-Polk K; Stewart J; Güner B; Hofilena B; Tjitro A; Anderson SD; Herman DS; Dellamary L; Swearingen CJ; Sunil KC; Yazici Y
    Aging Cell; 2019 Oct; 18(5):e13000. PubMed ID: 31267651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic Dyrk1 Inhibition Delays the Onset of AD-Like Pathology in 3xTg-AD Mice.
    Velazquez R; Meechoovet B; Ow A; Foley C; Shaw A; Smith B; Oddo S; Hulme C; Dunckley T
    Mol Neurobiol; 2019 Dec; 56(12):8364-8375. PubMed ID: 31240602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of ZJCK-6-46: A Potent, Selective, and Orally Available Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor for the Treatment of Alzheimer's Disease.
    Chen H; Gao X; Li X; Yu C; Liu W; Qiu J; Liu W; Geng H; Zheng F; Gong H; Xu Z; Jia J; Zhao Q
    J Med Chem; 2024 Aug; 67(15):12571-12600. PubMed ID: 39041662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dyrk1 inhibition improves Alzheimer's disease-like pathology.
    Branca C; Shaw DM; Belfiore R; Gokhale V; Shaw AY; Foley C; Smith B; Hulme C; Dunckley T; Meechoovet B; Caccamo A; Oddo S
    Aging Cell; 2017 Oct; 16(5):1146-1154. PubMed ID: 28779511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
    Ferrer I; Barrachina M; Puig B; Martínez de Lagrán M; Martí E; Avila J; Dierssen M
    Neurobiol Dis; 2005 Nov; 20(2):392-400. PubMed ID: 16242644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
    García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
    Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.
    Naert G; Ferré V; Meunier J; Keller E; Malmström S; Givalois L; Carreaux F; Bazureau JP; Maurice T
    Eur Neuropsychopharmacol; 2015 Nov; 25(11):2170-82. PubMed ID: 26381812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of selective dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors and their effects on tau and microtubule.
    Wu YW; HuangFu WC; Lin TE; Peng CH; Tu HJ; Sung TY; Sung TY; Yen SC; Pan SL; Hsu KC
    Int J Biol Macromol; 2024 Feb; 259(Pt 1):129074. PubMed ID: 38163507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.
    Jin N; Yin X; Gu J; Zhang X; Shi J; Qian W; Ji Y; Cao M; Gu X; Ding F; Iqbal K; Gong CX; Liu F
    J Biol Chem; 2015 Jun; 290(24):15219-37. PubMed ID: 25918155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of miR-26a-5p Suppresses Tau Phosphorylation and Aβ Accumulation in the Alzheimer's Disease Mice by Targeting DYRK1A.
    Liu Y; Wang L; Xie F; Wang X; Hou Y; Wang X; Liu J
    Curr Neurovasc Res; 2020; 17(3):241-248. PubMed ID: 32286945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a novel chemotype as DYRK1A inhibitors against Alzheimer's disease: Computational modeling and biological evaluation.
    Qiu N; Qian C; Guo T; Wang Y; Jin H; Yao M; Li M; Guo T; Lv Y; Si X; Wu S; Wang H; Zhang X; Xia J
    Int J Biol Macromol; 2024 Jun; 269(Pt 1):132024. PubMed ID: 38704072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.
    Kim H; Lee KS; Kim AK; Choi M; Choi K; Kang M; Chi SW; Lee MS; Lee JS; Lee SY; Song WJ; Yu K; Cho S
    Dis Model Mech; 2016 Aug; 9(8):839-48. PubMed ID: 27483355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
    Frost D; Meechoovet B; Wang T; Gately S; Giorgetti M; Shcherbakova I; Dunckley T
    PLoS One; 2011 May; 6(5):e19264. PubMed ID: 21573099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An inhibitor with GSK3β and DYRK1A dual inhibitory properties reduces Tau hyperphosphorylation and ameliorates disease in models of Alzheimer's disease.
    Liu X; Lai LY; Chen JX; Li X; Wang N; Zhou LJ; Jiang XW; Hu XL; Liu WW; Jiao XM; Qi ZT; Liu WJ; Wu LM; Huang YG; Xu ZH; Zhao QC
    Neuropharmacology; 2023 Jul; 232():109525. PubMed ID: 37004752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DYRK1A-mediated hyperphosphorylation of Tau. A functional link between Down syndrome and Alzheimer disease.
    Ryoo SR; Jeong HK; Radnaabazar C; Yoo JJ; Cho HJ; Lee HW; Kim IS; Cheon YH; Ahn YS; Chung SH; Song WJ
    J Biol Chem; 2007 Nov; 282(48):34850-7. PubMed ID: 17906291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DYRK1A inhibition as potential treatment for Alzheimer's disease.
    Stotani S; Giordanetto F; Medda F
    Future Med Chem; 2016 Apr; 8(6):681-96. PubMed ID: 27073990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.
    Demuro S; Sauvey C; Tripathi SK; Di Martino RMC; Shi D; Ortega JA; Russo D; Balboni B; Giabbai B; Storici P; Girotto S; Abagyan R; Cavalli A
    Eur J Med Chem; 2022 Feb; 229():114054. PubMed ID: 34959172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First selective dual inhibitors of tau phosphorylation and Beta-amyloid aggregation, two major pathogenic mechanisms in Alzheimer's disease.
    Mariano M; Schmitt C; Miralinaghi P; Catto M; Hartmann RW; Carotti A; Engel M
    ACS Chem Neurosci; 2014 Dec; 5(12):1198-202. PubMed ID: 25247807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.